Trial
NCT01970527
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Melanoma
Intervention
Ipilimumab
Why stopped
Change in standard of care
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-13